Tag Archives: Spark Therapeutics

Spark Therapeutics (ONCE) Receives a Hold from Mizuho Securities

In a report released today, Difei Yang from Mizuho Securities reiterated a Hold rating on Spark Therapeutics (ONCE – Research Report), with a price target of $114.50. The company’s shares opened today at $100.40. According to TipRanks.com, Yang is a

William Blair Believes Spark Therapeutics (NASDAQ: ONCE) Won’t Stop Here

William Blair analyst Raju Prasad initiated coverage with a Buy rating on Spark Therapeutics (ONCE – Research Report) yesterday. The company’s shares closed yesterday at $113.48, close to its 52-week high of $114.20. Prasad said: “We see a sound strategic

Analysts Offer Insights on Healthcare Companies: Spark Therapeutics (NASDAQ: ONCE) and Intercept Pharma (NASDAQ: ICPT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Spark Therapeutics (ONCE – Research Report) and Intercept Pharma (ICPT – Research Report). Spark Therapeutics (ONCE) Credit Suisse analyst Martin Auster maintained a Hold rating

William Blair Sticks to Their Buy Rating for Spark Therapeutics (ONCE)

William Blair analyst Raju Prasad maintained a Buy rating on Spark Therapeutics (ONCE – Research Report) today. The company’s shares opened today at $51.55. Prasad commented: “We continue to anticipate an update from SPK-8011 with prophylactic steroid therapy to treat

Cantor Fitzgerald Reiterates a Buy Rating on Spark Therapeutics (ONCE)

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Spark Therapeutics (ONCE – Research Report) on February 12 and set a price target of $80. The company’s shares closed on Friday at $52.77. According to TipRanks.com, Piros has 0

Spark Therapeutics (ONCE) Gets a Hold Rating from Credit Suisse

Credit Suisse analyst Martin Auster maintained a Hold rating on Spark Therapeutics (ONCE – Research Report) yesterday and set a price target of $44. The company’s shares closed yesterday at $47.44. According to TipRanks.com, Auster is a 3-star analyst with